Abstract-By mimicking sympathetic stimulation in vivo, we previously reported that mice globally lacking serotonin 5-HT 2B receptors did not develop isoproterenol-induced left ventricular hypertrophy. However, the exact cardiac cell type(s) expressing 5-HT 2B receptors (cardiomyocytes versus noncardiomyocytes) involved in pathological heart hypertrophy was never addressed in vivo. We report here that mice expressing the 5-HT 2B receptor solely in cardiomyocytes, like global 5-HT 2B receptor-null mice, are resistant to isoproterenol-induced cardiac hypertrophy and dysfunction, as well as to isoproterenol-induced increases in cytokine plasma-levels. These data reveal a key role of noncardiomyocytes in isoproterenol-induced hypertrophy in vivo. Interestingly, we show that primary cultures of angiotensinogen null adult cardiac fibroblasts are releasing cytokines on stimulation with either angiotensin II or serotonin, but not in response to isoproterenol stimulation, demonstrating a critical role of angiotensinogen in adrenergic-dependent cytokine production. We then show a functional interdependence between AT 1 Rs and 5-HT 2B receptors in fibroblasts by revealing a transinhibition mechanism that may involve heterodimeric receptor complexes. Both serotonin-and angiotensin II-dependent cytokine production occur via a Src/heparin-binding epidermal growth factor-dependent transactivation of epidermal growth factor receptors in cardiac fibroblasts, supporting a common signaling pathway. Finally, we demonstrate that 5-HT 2B receptors are overexpressed in hearts from patients with congestive heart failure, this overexpression being positively correlated with cytokine and norepinephrine plasma levels. Collectively, these results reveal for the first time that interactions between AT 1 and 5-HT 2B receptors coexpressed by noncardiomyocytes are limiting key events in adrenergic agonist-induced, angiotensin-dependent cardiac hypertrophy. Accordingly, antagonists of 5-HT 2B receptors might represent novel therapeutics for sympathetic overstimulation-dependent heart failure. 
C ardiac hypertrophy is a physiological adaptation of the heart to increased workload. Recent data challenged the widely held belief that cardiac hypertrophy is a necessary compensatory mechanism to maintain normal heart function. 1, 2 When sustained and extensive, cardiac hypertrophy can lead to maladaptation and progressive dysfunction leading to heart failure secondary to cardiomyocyte apoptosis and fibrosis. 3 In addition to biomechanical stress, several neurohumoral factors acting via G protein-coupled receptors (GPCRs), including ␤-adrenergic (␤-AR), endothelin and angiotensin (Ang) II type 1 (AT 1 R) receptors have been identified as potent inducers of cardiac hypertrophy. 4 -7 The chronic adrenergic stimulation experienced by patients with congestive heart failure (CHF) is a strong predictor of morbidity and mortality. Norepinephrine, through stimulation of ␤-ARs, is a well-known trigger of cardiac hypertrophy. The extent of left ventricular dysfunction in human pathology correlates to plasma norepinephrine concentration independently of arterial blood pressure. 8 Plasma levels of cytokines such as tumor necrosis factor (TNF)-␣ and interleukin (IL)-6 9 or transforming growth factor (TGF)-␤ 1 10 are also significantly increased in primary idiopathic hypertrophic cardiomyopathy. Noncardiomyocyte (cardiac fibroblast) stimulation by adrenergic agonists or Ang II can release growth factors, 11 endothelin-1, and cytokines including TNF-␣, IL-6, IL-1␤, and TGF-␤1. [12] [13] [14] Interestingly, several authors have demonstrated marked in vitro release of these hypertrophic factors by cardiac fibroblasts and suggested a causal link between this release and cardiomyocyte hypertrophy. The hypertrophic capacity of cytokines was also validated in vivo by the observation that mice with cardiac-restricted overexpression of TNF-␣, IL-6, or IL-1 exhibited cardiac hypertrophy. [15] [16] [17] The question of whether ␤-AR stimulation promotes pathological cardiac hypertrophy by a direct effect on myocytes and/or nonmyocytes remains debatable. In vitro, most of the investigators used neonatal rat cardiomyocytes and found that the ␤-AR agonist, isoproterenol (ISO), leads to a mild hypertrophy of these cells, the hypertrophy being stronger in presence of cardiac fibroblast-conditioned medium. 18 However, it was reported that ISO had no hypertrophic effects on adult rat myocytes, 19, 20 suggesting that noncardiomyocytes could participate in ␤-adrenergic-dependent cardiac hypertrophy in an in vivo adult context.
Using a genetic approach, we previously showed that serotonin 5-HT 2B receptors (5-HT 2B Rs) have a trophic action on newborn cardiomyocytes in vitro 21 and by ␣-myosin heavy chain (␣-MHC)-dependent 5-HT 2B R overexpression in cardiomyocytes in vivo. 22 The initial cardiomyopathy of 5-HT 2B R mutant mice is compensated over time in the absence of hypertrophic stage. 23 Thus, we studied their response to a pathological hypertrophic stimulus using chronic ISO infusion as a model of sympathetic stimulation in vivo. We reported that either total genetic (5-HT 2B R mutant mice) or pharmacological (SB206553 or SB215505, 5-HT 2B R antagonists) blockade of 5-HT 2B R function completely prevented ISO-induced cardiac hypertrophy. 13 Recently, 5-HT 2B Rs were shown to be required for left ventricular hypertrophy in another model of cardiac hypertrophy (Ang II chronic infusion). 24 Nevertheless, neither the exact cardiac cells requiring 5-HT 2B Rs (cardiomyocytes versus fibroblasts), the receptor crosstalk nor their transduction pathway has been addressed in in vivo models of pathological cardiac hypertrophy.
The purpose of this study was to determine: (1) whether 5-HT 2B R expression in cardiomyocytes is required for ISOinduced left ventricular hypertrophy; (2) whether Ang II participates in ␤-AR-dependent cardiac hypertrophy in vivo; (3) which epistatic relationships exist between ␤-AR-, AT 1 R-, and 5-HT 2B R-dependent hypertrophic factor release; and (4) whether similar mechanisms could be found in human CHF. 
Materials and Methods

Generation of 5-HT 2B R Transgenic Mice and Genotyping
Generation of ␣-MHC-5-HT 2B ϩ/Ϫ (Tg) mice and 5-HT 2B Ϫ/Ϫ mice has been described previously. 22, 25 All animal experiments were performed in accordance with institutional guidelines and European regulations.
Induction of Cardiac Hypertrophy by ISO
In 11-week-old male mice, ISO (30 mg/kg per day), was delivered for 7 days by miniosmotic pumps (1007D, Alzet Corp) implanted subcutaneously under anesthesia (0.75% isoflurane).
Cardiovascular Phenotyping by Echocardiography
Left ventricular dimension and heart rate were assessed before and after ISO infusion under isoflurane anesthesia (0.75%) by echocar- diography. 13 After echocardiographic analysis, mice were euthanized by CO 2 and weighed.
Analysis of 5-HT 2 R and AT 1 R Expression by Binding Assays
Membrane proteins prepared from heart ventricles or from adult mouse cardiac fibroblast or myocytes primary cultures were analyzed by binding studies to assess receptor expression. 23 
Patients
Cardiac samples were obtained from explant grafts except for normal controls, the tissue of which was obtained from donors without recipient. ELISAs for plasma concentration for cytokines were performed. The local ethical committee (Comité Consultatif de Protection des Personnes se Prétant à la Recherche Biomédicale, CCPPRB d'Alsace) approved the study, and all patients gave their informed consent before tissue collection and plasma collection. For frozen human heart sections, all harvest and use of human tissue was performed in accordance with NIH and University of Rochester Medical Center institutional review board guidelines.
Adult Cardiac Fibroblasts Primary Culture
Cultures of ventricular noncardiomyocytes were obtained by differential plating from dissociated heart of male adults mice (10 to 12 weeks) or from neonatal rat hearts (3 to 4 days). Cardiac fibroblasts used during early passages were identified by characteristic morphology and positive staining with antibody to vimentin (Ͼ90%) 13 and negative staining for macrophage marker F4/80 26 (Ͻ1%) ( Figure  II in the online data supplement). One day before the experiments, the cells were serum-starved.
Measurement of Cytokines in Plasma and Culture Supernatants
Concentrations of Ang II, IL-6, IL-1␤, TNF-␣, and TGF-␤ 1 were measured in plasma and culture supernatants by ELISA kits (Bertin, DY 406, DY 401, DY 410 and DY 1679, R&D systems). 13 
Confocal Imaging
Cells or tissues were observed after 4% paraformaldehyde fixation and revealed using either a mouse monoclonal anti-FLAG M2 (Sigma, 1:100), a rabbit anti-GFP antibody (Santa Cruz Biotechnology, 1:100), a monoclonal anti-5-HT 2B R antibody (Pharmingen,1:100), a rabbit anti-AT 1 R (N-10, Santa Cruz Biotechnology, 1:100) or a rabbit anti-Vimentin (Santa Cruz Biotechnology, 1:200).
Immunoprecipitation and Western Blotting
Serum-starved cells were homogenized at 4°C in RIPA buffer, centrifuged at 10 000g, and incubated with either anti-FLAG affinity matrix (40 L, Sigma) overnight at 4°C or a monoclonal anti-5-HT 2B R antibody (Pharmingen, 2 g). Western blot analysis of immunoprecipitated samples was performed on SDS-PAGE 10% gels and revealed using either a rabbit anti-GFP antibody (Santa Cruz Biotechnology, 1:1000) or a rabbit anti-AT 1 R (N-10, Santa Cruz Biotechnology, 1:1000).
Data Analysis and Statistics
All results are expressed as meansϮSEM. Different groups were compared through 1-way ANOVA, followed by Newman-Keuls test. All calculations were performed using the GraphPad Prism 4.0 program.
Results
Expression of 5-HT 2B Rs by Noncardiomyocytes Is Required for ISO-Induced Cardiac Hypertrophy
We first verified the expression of 5-HT 2B Rs and AT 1 Rs either by immunohistochemistry of human adult left ventricles (Figure (Figure 2c ). As expected after ISO infusion, a similar heart rate increase was observed in all 4 genotypes (ϩ25%) (supplemental Table I ). By echocardiography, ISO infusion led to cardiac hypertrophy in Tg; 5-HT 2B ϩ/ϩ and in Tg; 5-HT 2B ϩ/Ϫ mice as shown by increased left ventricular mass-to-body weight ratio (ϩ30%) (Figure 3a and supplemental Table I 
5-HT 2B Rs and AT 1 Rs Colocalize and Coimmunoprecipitate
By confocal microscopy, we first observed membrane colocalization of 5-HT 2B Rs and AT 1 Rs in rat cardiac fibroblasts (Figure 6a ). After immunoprecipitation of neonatal rat cardiac fibroblast extracts with an anti-5-HT 2B R antibody, we detected bands of 41 to 43 kDa (expected molecular mass for AT 1 Rs) similar to those observed by direct Western blot analysis (Figure 6a ) with an anti-AT 1 R antibody. We further confirm these putative interactions, using HEK293 transfected cells with FLAG-tagged human AT 1 Rs and CFPtagged human 5-HT 2B Rs, that showed membrane colocalization (Figure 6b ). After immunoprecipitation with an anti-FLAG antibody, we probed Western blots of immunoprecipitations with an anti-GFP antibody. We detected a single band of 80 kDa (the expected molecular mass of the CFP-5-HT 2B R) only in cotransfected cells (Figure 6b) . These results strongly suggest that AT 1 Rs and 5-HT 2B Rs colocalize and may directly interact in common signaling complexes in transfected cells.
5-HT 2B R Overexpression in Human Heart Failure
Because 5-HT 2B Rs were also expressed in both human cardiac fibroblasts and cardiomyocytes (Figure 1) , we assessed a putative contribution of 5-HT 2B Rs in human CHF. We looked for 5-HT 2B R expression in left ventricular biopsies of 16 CHF patients, compared to 7 normal control subjects. Expression of 5-HT 2B Rs, obtained from biopsies of left ventricles, were found to be significantly elevated in samples from failing hearts (Figure 7a) . This increase appears to be independent of cardiomyopathy etiology, severity of the disease, or treatments (supplemental Table II ). However, significant correlations were found between cardiac 5-HT 2B R expression levels and plasma concentrations of either norepinephrine, IL-6, TGF-␤, or TNF-␣ in CHF patients (Figure 7b Table II ). Taken together, these data support the notion that 5-HT 2B R expression is linked to cardiac cytokine production during the sympathetic overactivity associated with CHF.
Discussion
In light of our previous reports, 5-HT 2B Rs participate in trophic responses of the myocardium by acting directly on cardiomyocytes 21, 22 or indirectly on noncardiomyocytes through the release of paracrine factors induced by chronic ISO stimulation. 13 By reexpressing the 5-HT 2B R selectively into cardiomyocytes in a 5-HT 2B R-null background, we describe here for the first time that its expression by noncardiomyocytes is absolutely required for ISO-induced cardiac hypertrophy. The ISO-mediated increases in TNF-␣, TGF-␤, IL-6, and IL-1␤ plasma levels observed in the wild-type mice also require 5-HT 2B R expression in noncardiomyocytes.
No increase in plasma Ang II could be detected after ISO infusion in mice but Ang II can be produced in the heart through a local renin-angiotensin system. 30 Interestingly, angiotensinogen mRNA and protein levels are increased by ␤-AR stimulation in neonatal cardiac fibroblasts, 31 which were shown, as opposed to cardiomyocytes, to serve as the predominant source of IL-6 after ISO stimulation in mouse myocardium. In our study, we uncover the Ang II/AT 1 R axis critical role for ISO-induced cytokine release in adult cardiac fibroblasts as validated by several observations. (1) A significant increase in Ang II, but not in 5-HT, was detected in supernatants of adult mouse cardiac fibroblast culture after ISO stimulation. (5) Finally, using ZD7155, we show that AT 1 Rs are also required for ISO-induced cytokine release. Together, these data reveal, for the first time, that ISO-dependent Ang II production by cardiac fibroblasts leading to the autocrine AT 1 R stimulation is absolutely required for hypertrophic cytokine release in heart.
The present report addresses unknowns regarding the AT 1 R and 5-HT 2B R signaling pathway(s) controlling cytokine release in cardiac fibroblasts. In the present work, we demonstrate that expression of HB-EGF and Src activity are critical for either an Ang II-or a 5-HT-dependent cytokine release process. We show that MMPs are responsible for HB-EGF shedding and subsequent EGF-R transactivation that is induced by GPCR agonists such as Ang II or 5-HT. 32, 33 TNF-␣-converting enzyme (TACE) (ADAM-17) was found to control HB-EGF shedding in fibroblasts, 34 and a recent report indicated that 5-HT 2B Rs can directly regulate this enzyme activity in neuronal cells. 35 Our work also highlights the importance of p38 but not ERK1/2 pathway for cytokine release. In summary, our data support the following epistatic relationships (Figure 8 and online data and video): ISOfAng IIf5-HT 2B ϩAT 1 RsfSrcfMMPsfHB-EGFfErbB-1/4-Rsfp38fIL-6, TNF-␣, TGF-␤, and IL-1␤ release. All of these findings support that AT 1 Rs and 5-HT 2B Rs share common EGF-R-dependent signaling pathways in adult cardiac fibroblasts.
Blockade of 1 of the 2 receptors prevents cytokine release induced by the other receptor, supporting interactions between 5-HT 2B Rs and AT 1 Rs. Using coimmunolocalization and a pull-down assay, we show that the 2 receptors interact in a common cell compartment. Recently, reports have suggested that GPCRs exist in heterodimeric complexes that may play a key role in receptor maturation and trafficking to the plasma membrane and/or signaling (for review, see Bulenger et al 36 ). The protein network associated with the C terminus of the 5-HT 2 Rs includes scaffolding proteins containing 1 or several PDZ domains, signaling proteins and proteins of the cytoskeleton that may be involved in signaling complexes. 37 More work will be necessary to conclude whether in vivo interactions between AT 1 Rs and 5-HT 2B Rs are direct or mediated by adaptor proteins. Only a few reports have described an inhibitory mechanism in trans between 2 GPCRs. To our knowledge, this process was first described between AT 1 Rs and ␤ 2 -ARs in COS-7 cells that express equal endogenous levels of AT 1 Rs and ␤ 2 -ARs and was also shown to occur in adult cardiomyocytes. 38 Together, our findings are consistent with the hypothesis that AT 1 Rs and 5-HT 2B Rs exist in common signaling complexes and that they may interact together.
The increase of 5-HT 2B R sites in biopsies of left ventricles from CHF patients that we observed appears independent of the type of cardiopathy, its duration, or the treatments (including ␤ blockers or ACE inhibitors). In recent cardiac transcriptome analysis, an increase in 5-HT 2B R mRNA was also reported in human 39 or rat 40 failing heart tissue, during the functional recovery of end-stage human heart failure, 41 and in rats after banding of the ascending aorta. 42, 43 The significant correlation between 5-HT 2B R expression and cytokines IL-6, TNF-␣, or TGF-␤ plasma levels supports, in humans, our findings in mice. Interestingly, the significant correlations with sympathetic activity found in patients indicate that 5-HT 2B Rs are as well required for adrenergicdependent cytokines production in humans. A cardiac hypertrophy-associated switch of adult to fetal genes has been reported. It is tempting to speculate that similar mechanisms might be operative at 5-HT 2B receptor expression, which is expressed in embryonic heart. Sympathetic overstimulation may also participate via cAMP-dependent regulation as an autocrine regulatory loop. 35 In summary, our data indicate that a selective 5-HT 2B R antagonist blocks both Ang II and adrenergic adverse effects in pathological conditions with no alterations of hemodynamics or blood pressure.
